Find the right fit for you - faster
Get tailored insights about working at Sequel Med Tech in one quick step.
Sequel Med Tech Snapshot
To be the automated insulin delivery (AID) experience of choice for people living with diabetes
Founded in 2023 and headquartered in Manchester, N.H., Sequel Med Tech is a company developing the next generation of transformative drug-delivery advancements. Sequel’s approach is to look at disease management holistically to advance systems that make living with disease simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare visionary Alan Lotvin, MD to bring the latest developments in science and technology to market to help drive more accessible drug delivery. Sequel’s first product, the twiist™ Automated Insulin Delivery (AID) system powered by Tidepool recently received FDA clearance and is indicated for people ages 6 and up with type 1 diabetes. For more information, visit sequelmedtech.com and twiist.com.
